Biogen-Idec Prevails Over Genentech In Arbitration For Control Of Rituximab
This article was originally published in The Pink Sheet Daily
Executive Summary
Arbitrator rules that 2003 merger combining Biogen and Idec does not forfeit company’s rituximab rights via a change-of-control.